scholarly journals Real-World Observational Study on the Characteristics and Treatment Patterns of Allergic Asthma Patients Receiving Omalizumab in Canada

2020 ◽  
Vol Volume 14 ◽  
pp. 725-735
Author(s):  
Jason K Lee ◽  
Suvina Amin ◽  
Michelle Erdmann ◽  
Atif Kukaswadia ◽  
Jelena Ivanovic ◽  
...  
Keyword(s):  
Observational Study ◽  
Allergic Asthma ◽  
Real World ◽  
Treatment Patterns ◽  
Asthma Patients

P212 A real-world assessment of omalizumab treatment patterns in asthma patients newly treated with omalizumab

2017 ◽  
Vol 119 (5) ◽  
pp. S53
Author(s):  
X. Ke ◽  
A. Kavati ◽  
D. Wertz ◽  
Q. Huang ◽  
L. Wang ◽  
...  
Keyword(s):  
Real World ◽  
Treatment Patterns ◽  
Asthma Patients

Treatment Patterns of Newly Diagnosed Asthma Patients in an Urban Setting in China: A Retrospective Longitudinal Real World Evidence Study

2021 ◽  
Author(s):  
Zhizhen Hu ◽  
Jianwei Xuan ◽  
Haijin Zhao ◽  
Hangming Dong ◽  
Changhui Yu ◽  
...  
Keyword(s):  
Real World ◽  
Asthma Management ◽  
Treatment Patterns ◽  
Initial Diagnosis ◽  
Urban Setting ◽  
Asthma Treatment ◽  
Newly Diagnosed ◽  
Asthma Patients ◽  
Controller Medications

Abstract Background: Asthma is prevalent but largely undiagnosed and undertreated in China. Despite readily available effective therapies, the outcomes still leave much to be desired. There is a scarcity of data describing the treatment patterns of patients with newly diagnosed asthma in real world settings. The main goal of this study was to investigate treatment patterns of newly diagnosed asthma patients with up to 1 year follow-up to gain a better understanding of gaps of optimal asthma management in China.Methods: We conducted a large-scale of retrospective cohort analysis of asthma treatment for newly diagnosed patients using an electronic medical record database (SuValue). Eligible patients were at least 14 years old at the diagnosis from 2001 to March 2019. We categorized anti-asthmatic medication use by its classes and documented their use by the underlying disease severity. To examine the use of controlled medications over follow-ups, we summarized their utilization over consecutive 3-month time windows from the initial diagnosis to the end of follow-up. Results: A total of 26,301 patients from tertiary (25.24%), secondary (71.83%) and primary (2.92%) hospitals were included in the study; 54.01% received one or more controller medications during the study period and 30.4% had 12 months of follow-up visits. Initial prescriptions were inhaled corticosteroid (ICS)-containing controller treatment (13.9%), other controller treatment (31.59%), anti-asthmatic relivers (23.76%), symptomatic medications (14.54%) and no medication (16.2%). Patients mostly discontinued their controller prescriptions within 6 months after the initial diagnosis. Of the 45.98% patients not receiving any controller medication, 70.16% used relivers or symptomatic medications during follow-up visits. In patients who had 12-month follow-up visits, 76.86%, 17.25%, 5.88% were deemed to have mild, moderate, and severe asthma, respectively, during the 1st 3 months. Percentages of severe and moderate asthma patients were halved by the 2nd 3-month landmark and remained stable over the remaining follow-up visits. There were significant differences in asthma treatment between tertiary and secondary hospitals.Conclusion: In newly diagnosed asthma patients, controller medications were significantly underused while symptom-relief drugs, on the other hand, appeared to be overused. Poor adherence to current guidelines were common and more noticeable in lower tiered hospitals. These findings call for needs of more aggressive asthma management and more educational efforts in China.

scholarly journals The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study

PLoS ONE ◽  
2017 ◽  
Vol 12 (8) ◽  
pp. e0183869 ◽  
Author(s):  
Mohit Bhutani ◽  
William H. Yang ◽  
Jacques Hébert ◽  
Frederica de Takacsy ◽  
Jean-Louis Stril
Keyword(s):  
Observational Study ◽  
Allergic Asthma ◽  
Real World ◽  
The Real ◽  
Severe Allergic Asthma

scholarly journals Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on Omalizumab

2018 ◽  
Vol 9 ◽  
pp. 215265671876338
Author(s):  
Abhishek Kavati ◽  
Dominic Pilon ◽  
Benjamin Ortiz ◽  
Brandee Paknis ◽  
Ashok Vegesna ◽  
...  
Keyword(s):  
Allergic Asthma ◽  
Real World ◽  
Index Date ◽  
Immunoglobulin E ◽  
The United States ◽  
Uncontrolled Asthma ◽  
Asthma Control Test ◽  
Severe Allergic Asthma ◽  
Asthma Patients ◽  
Baseline Characteristics

Background Indication of omalizumab in the United States was recently extended to include pediatric (6–11 years) uncontrolled moderate-to-severe allergic asthma patients. Objective The purpose of this study was to describe baseline characteristics of this population from a real-world dataset. Methods Allergic asthma patients and uncontrolled moderate-to-severe allergic asthma patients, aged 6–11 years, were identified in the Allergy Partners Network Electronic Medical Records (2007–2016). The index date for allergic asthma patients was the latest between the second asthma-related visit and the allergic status confirmation. Uncontrolled moderate-to-severe allergic asthma patients were stratified into omalizumab-exposed (index date) or omalizumab-unexposed (index date randomly generated) groups. Characteristics were evaluated during the 12-month preindex period. Results A total of 5806 allergic asthma, 37 omalizumab-exposed, and 2620 omalizumab-unexposed patients were selected (mean age approximately 9 years). Allergic asthma and omalizumab-unexposed patients were predominantly white (70.2% and 61.2%) whereas the majority of omalizumab-exposed were African Americans (62.2%). Mean immunoglobulin E was 782.0 IU/ml in allergic asthma patients (available in 2.2%), 1134.4 IU/ml in omalizumab-exposed (available in 100.0%), and 746.1 IU/ml in omalizumab-unexposed (available in 3.1%). Allergic asthma patients were less severe than omalizumab-exposed and omalizumab-unexposed based on the forced expiratory volume in 1 s as a percentage of predicted value (FEV1% predicted) and the Childhood Asthma Control Test (C-ACT). FEV1% predicted was below normal (<80%) in 42.4% of omalizumab-exposed and 39.1% of omalizumab-unexposed patients, also 63.6% of omalizumab-exposed and 46.7% of omalizumab-unexposed had uncontrolled asthma (C-ACT score <20). In African American omalizumab-exposed patients, FEV1% predicted was below normal in 47.6% and 55.0% had uncontrolled asthma. Conclusions In a real-world setting, pediatric patients with uncontrolled moderate-to-severe allergic asthma have a significant disease burden as shown by high rates of poor lung function, disease control, and symptoms. Currently available treatments could help improve disease management in this population.

scholarly journals Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients

Pulmonology ◽  
2020 ◽  
Author(s):  
A. Arrobas ◽  
M.P. Barbosa ◽  
S. Rabiais ◽  
B. Vandewalle ◽  
J. Félix
Keyword(s):  
Cost Effectiveness ◽  
Allergic Asthma ◽  
Real World ◽  
Asthma Patients
Sign in / Sign up

Export Citation Format

Share Document